Ignite Creation Date:
2025-12-24 @ 2:08 PM
Ignite Modification Date:
2025-12-24 @ 2:08 PM
Study NCT ID:
NCT07178795
Status:
RECRUITING
Last Update Posted:
2025-11-17
First Post:
2025-09-11
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Sponsor:
Sichuan Baili Pharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-09-29
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-12
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-11
First Submit QC Date:
None
Study First Post Date:
2025-09-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-13
Last Update Post Date:
2025-11-17
Last Update Post Date Type:
ESTIMATED